Omega Diagnostics Group PLC COVID-19 Consortium MOU (2892J)
09 April 2020 - 4:00PM
UK Regulatory
TIDMODX
RNS Number : 2892J
Omega Diagnostics Group PLC
09 April 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Memorandum of Understanding
COVID-19 Consortium
Omega (AIM: ODX), the medical diagnostics company focused on
CD4, food intolerance and allergy testing announces that it has
signed a Memorandum of Understanding ("MOU") with three other
companies from across the UK, in conjunction with the University of
Oxford to form the UK Rapid Test Consortium ("UK-RTC") in order to
jointly develop and manufacture a COVID-19 Point of Care antibody
test as part of the Government's five pillar national testing
strategy for COVID-19.
The UK-RTC, which was announced by the UK Government yesterday,
comprises Omega, Abingdon Health Limited, BBI Solutions Limited,
CIGA Healthcare Limited, and the University of Oxford (the
"Parties") and was formed at the request of the UK Government to
support the development and manufacturing scale-up of a COVID-19
lateral flow antibody test ("COVID-19 Rapid Test") to determine
whether people have developed immunity after contracting the
virus.
The MOU is for an initial period of six months and the Parties
will collaborate to utilise their combined lateral flow test design
and manufacturing expertise to optimise the design for potential
accelerated scale-up to manufacturing of the COVID-19 Rapid
Test.
Once the COVID-19 Rapid Test reaches design freeze, then the
specification and standard operating procedures will be shared with
each party of the consortium to enable manufacturing and/or
assembly to be undertaken at each site, including at Omega's
manufacturing facility in Alva, Scotland, according to
capability.
Colin King, CEO of Omega commented: "We are delighted to be part
of this consortium and to support the Scottish and UK Governments'
efforts to combat the Coronavirus pandemic and look forward to
using Omega's manufacturing knowledge and capabilities in
supporting and furthering this objective."
The information communicated in this announcement is inside
information for the purposes of Article 7 of EU Regulation
596/2014.
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030
Bill Rhodes, Interim Non-Executive www.omegadiagnostics.com
Chairman
Colin King, Chief Executive
Kieron Harbinson, Group Finance
Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Hannah Boros (Corporate
Finance)
Camille Gochez (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSSSESAESSEDL
(END) Dow Jones Newswires
April 09, 2020 02:00 ET (06:00 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From May 2023 to May 2024